| Dr Francisco Delacruz-newlan, MD | |
|
1005 Broadway St, Quincy, IL 62301-2834 | |
| (217) 223-1200 | |
| Not Available |
| Full Name | Dr Francisco Delacruz-newlan |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 29 Years |
| Location | 1005 Broadway St, Quincy, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922006451 | NPI | - | NPPES |
| 7215DE | Other | WA | REGENCE BLUE SHIELD |
| 8366148 | Medicaid | WA | |
| 910847215 | Other | WA | UNIFORM MEDICAL |
| 016487001 | Other | WA | GROUP HEALTH CORP |
| 910847215 | Other | WA | PREMERA BLUE CROSS |
| P00055294 | Other | WA | RAILROAD MEDICARE |
| A035 | Other | WA | TRIWEST (CHAMPUS) |
| 0172507 | Other | WA | LABOR AND INDUSTRIES |
| 910847215-36 | Other | WA | KPS NUMBER |
| 8932656 | Other | WA | VICTIMS OF CRIME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 2008009075 (Missouri) | Secondary |
| 207L00000X | Anesthesiology | 036.099670 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Blessing Hospital | Quincy, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Blessing Hospital | 3072422534 | 345 |
News Archive
A review of previous studies indicates that use of a class of medications known as "incretin-based therapy", which act via certain pathways that affect glucose metabolism may provide modest effectiveness and favorable weight change outcomes for the treatment of type 2 diabetes and may represent an alternative to other hypoglycemic therapies.
ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.
Numerous previous attempts to develop therapeutic treatments, directed at discreet targets of the sepsis cascade, could not cope with the complex pathophysiology of sepsis and failed.
Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.
Taking the first step and getting medical help for joint pain can be hard, but for autoimmune conditions like rheumatoid arthritis, delaying treatment can lead to increased permanent joint damage and disability.
› Verified 1 days ago
| Entity Name | Sarah Bush Lincoln Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669564662 PECOS PAC ID: 5092614867 Enrollment ID: O20031231000478 |
News Archive
A review of previous studies indicates that use of a class of medications known as "incretin-based therapy", which act via certain pathways that affect glucose metabolism may provide modest effectiveness and favorable weight change outcomes for the treatment of type 2 diabetes and may represent an alternative to other hypoglycemic therapies.
ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.
Numerous previous attempts to develop therapeutic treatments, directed at discreet targets of the sepsis cascade, could not cope with the complex pathophysiology of sepsis and failed.
Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.
Taking the first step and getting medical help for joint pain can be hard, but for autoimmune conditions like rheumatoid arthritis, delaying treatment can lead to increased permanent joint damage and disability.
› Verified 1 days ago
| Entity Name | Blessing Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255515342 PECOS PAC ID: 3072422534 Enrollment ID: O20040330001155 |
News Archive
A review of previous studies indicates that use of a class of medications known as "incretin-based therapy", which act via certain pathways that affect glucose metabolism may provide modest effectiveness and favorable weight change outcomes for the treatment of type 2 diabetes and may represent an alternative to other hypoglycemic therapies.
ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.
Numerous previous attempts to develop therapeutic treatments, directed at discreet targets of the sepsis cascade, could not cope with the complex pathophysiology of sepsis and failed.
Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.
Taking the first step and getting medical help for joint pain can be hard, but for autoimmune conditions like rheumatoid arthritis, delaying treatment can lead to increased permanent joint damage and disability.
› Verified 1 days ago
| Entity Name | North American Partners In Anesthesia Illinois Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699032524 PECOS PAC ID: 1052576519 Enrollment ID: O20120706000534 |
News Archive
A review of previous studies indicates that use of a class of medications known as "incretin-based therapy", which act via certain pathways that affect glucose metabolism may provide modest effectiveness and favorable weight change outcomes for the treatment of type 2 diabetes and may represent an alternative to other hypoglycemic therapies.
ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.
Numerous previous attempts to develop therapeutic treatments, directed at discreet targets of the sepsis cascade, could not cope with the complex pathophysiology of sepsis and failed.
Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.
Taking the first step and getting medical help for joint pain can be hard, but for autoimmune conditions like rheumatoid arthritis, delaying treatment can lead to increased permanent joint damage and disability.
› Verified 1 days ago
| Entity Name | Resource Anesthesiology Associates Of Il Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750347829 PECOS PAC ID: 5698006641 Enrollment ID: O20191007000960 |
News Archive
A review of previous studies indicates that use of a class of medications known as "incretin-based therapy", which act via certain pathways that affect glucose metabolism may provide modest effectiveness and favorable weight change outcomes for the treatment of type 2 diabetes and may represent an alternative to other hypoglycemic therapies.
ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.
Numerous previous attempts to develop therapeutic treatments, directed at discreet targets of the sepsis cascade, could not cope with the complex pathophysiology of sepsis and failed.
Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.
Taking the first step and getting medical help for joint pain can be hard, but for autoimmune conditions like rheumatoid arthritis, delaying treatment can lead to increased permanent joint damage and disability.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Francisco Delacruz-newlan, MD 1010 Sylvan Way, Bremerton, WA 98310-2826 Ph: (360) 479-3657 | Dr Francisco Delacruz-newlan, MD 1005 Broadway St, Quincy, IL 62301-2834 Ph: (217) 223-1200 |
News Archive
A review of previous studies indicates that use of a class of medications known as "incretin-based therapy", which act via certain pathways that affect glucose metabolism may provide modest effectiveness and favorable weight change outcomes for the treatment of type 2 diabetes and may represent an alternative to other hypoglycemic therapies.
ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.
Numerous previous attempts to develop therapeutic treatments, directed at discreet targets of the sepsis cascade, could not cope with the complex pathophysiology of sepsis and failed.
Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.
Taking the first step and getting medical help for joint pain can be hard, but for autoimmune conditions like rheumatoid arthritis, delaying treatment can lead to increased permanent joint damage and disability.
› Verified 1 days ago
Joseph Valentine Meyer, MD Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 1005 Broadway St, Quincy, IL 62301 Phone: 217-223-8400 | |
Linh Thuy Nguyen, M.D. Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 1005 Broadway St, Quincy, IL 62301 Phone: 217-223-8400 | |
Margaret Isabel Thirston, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3301 Broadway St, Quincy, IL 62301 Phone: 217-277-4090 | |
Dr. Ryan Mack Leifheit, MD Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 1005 Broadway St, Quincy, IL 62301 Phone: 217-223-8400 | |
William Mizikar, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3301 Broadway St, Quincy, IL 62301 Phone: 217-222-6550 | |
Merle W Jacobs, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 3021 Old Orchard Rd, Quincy, IL 62305 Phone: 217-222-6858 | |
Jeffrey Amport, M.D. Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 1005 Broadway St, Quincy, IL 62301 Phone: 217-223-8400 |